1. Home
  2. TNGX vs KTF Comparison

TNGX vs KTF Comparison

Compare TNGX & KTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • KTF
  • Stock Information
  • Founded
  • TNGX 2014
  • KTF 1988
  • Country
  • TNGX United States
  • KTF United States
  • Employees
  • TNGX N/A
  • KTF N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • KTF Finance Companies
  • Sector
  • TNGX Health Care
  • KTF Finance
  • Exchange
  • TNGX Nasdaq
  • KTF Nasdaq
  • Market Cap
  • TNGX 317.4M
  • KTF 350.7M
  • IPO Year
  • TNGX N/A
  • KTF N/A
  • Fundamental
  • Price
  • TNGX $1.29
  • KTF $8.96
  • Analyst Decision
  • TNGX Strong Buy
  • KTF
  • Analyst Count
  • TNGX 7
  • KTF 0
  • Target Price
  • TNGX $12.33
  • KTF N/A
  • AVG Volume (30 Days)
  • TNGX 756.3K
  • KTF 103.3K
  • Earning Date
  • TNGX 05-07-2025
  • KTF 01-01-0001
  • Dividend Yield
  • TNGX N/A
  • KTF 3.54%
  • EPS Growth
  • TNGX N/A
  • KTF N/A
  • EPS
  • TNGX N/A
  • KTF 0.39
  • Revenue
  • TNGX $42,069,000.00
  • KTF N/A
  • Revenue This Year
  • TNGX N/A
  • KTF N/A
  • Revenue Next Year
  • TNGX N/A
  • KTF N/A
  • P/E Ratio
  • TNGX N/A
  • KTF $23.10
  • Revenue Growth
  • TNGX 15.17
  • KTF N/A
  • 52 Week Low
  • TNGX $1.11
  • KTF $7.40
  • 52 Week High
  • TNGX $12.02
  • KTF $9.12
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 37.63
  • KTF 33.80
  • Support Level
  • TNGX $1.25
  • KTF $8.93
  • Resistance Level
  • TNGX $1.44
  • KTF $9.03
  • Average True Range (ATR)
  • TNGX 0.15
  • KTF 0.13
  • MACD
  • TNGX 0.03
  • KTF -0.02
  • Stochastic Oscillator
  • TNGX 45.00
  • KTF 28.00

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

About KTF DWS Municipal Income Trust

DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.

Share on Social Networks: